Aradigm's AERx inhaler "safe" for interferon:
This article was originally published in Clinica
In what is claimed to be the first human trial of interferon-alpha 2b inhalation, Aradigm says its AERx pulmonary drug delivery device was "safe and well tolerated" in healthy volunteers. The advantage of pulmonary delivery over conventional subcutaneous injection of interferon-alpha 2b is that it could reduce the dosage needed to achieve a therapeutic effect. This in turn may reduce adverse events, such as flu-like symptoms, that are associated with injection, says the Hayward, California firm.